Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Biogen Inc.
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.
IPO Date: January 3, 1994
Sector: Healthcare
Industry: Biotech
Market Cap: $21.5B
Activated in VL: True
Average Daily Range
Avg Daily Range: $2.46 | 1.33%
Avg Daily Range (30 D): $2.29 | 1.57%
Avg Daily Range (90 D): $2.07 | 1.52%
Institutional Daily Volume
Avg Daily Volume: 2.07M
Avg Daily Volume (30 D): 1.36M
Avg Daily Volume (90 D): 1.18M
Trade Size
Avg Trade Size (Sh.): 107
Avg Trade Size (Sh.) (30 D): 40
Avg Trade Size (Sh.) (90 D): 39
Institutional Trades
Total Inst.Trades: 44,222
Avg Inst. Trade: $6.05M
Avg Inst. Trade (30 D): $11.03M
Avg Inst. Trade (90 D): $10.86M
Avg Inst. Trade Volume: .04M
Avg Inst. Trades (Per Day): 8
Market Closing Trades
Avg Closing Trade: $27.85M
Avg Closing Trade (30 D): $37.41M
Avg Closing Trade (90 D): $33.13M
Avg Closing Volume: 135.08K
   
News
Oct 22, 2025 @ 12:00 PM
Cassava Sciences Appoints Dawn C. Bir to the Board...
Source: Cassava Sciences, Inc.
Oct 14, 2025 @ 5:52 PM
CD40 Targeting Therapy Clinical Trials Anti CD40 A...
Source: Not Specified
Oct 13, 2025 @ 11:30 PM
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutane...
Source: Eisai And Biogen
Oct 2, 2025 @ 4:15 PM
6 Healthcare Stocks Positioned to Soar After Trump...
Source: David Wagner
Sep 28, 2025 @ 11:30 PM
“LEQEMBI®” (lecanemab) IV Maintenan...
Source: Eisai Co., Ltd. And Biogen Inc.
Financials
  TTM Q2 2025 Q1 2025
Basic EPS $4.33 $1.65
Diluted EPS $4.33 $1.64
Revenue $ $ 2.65B $ 2.43B
Gross Profit $ $ 2.04B $ 1.8B
Net Income / Loss $ $ 634.8M $ 240.5M
Operating Income / Loss $ $ 744M $ 311.2M
Cost of Revenue $ $ 605M $ 629.3M
Net Cash Flow $ $ 160.5M $ 223.3M
PE Ratio    
Splits
Jan 18, 2001:   3:1